bioMérieux Presents 2013 Sonnenwirth Award for Leadership in Clinical Microbiology to Roberta B. Carey, Ph.D. of the Centers for Disease Control and Prevention (CDC)

20 May, 2013

bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce Roberta B. Carey, Ph.D as the 2013 recipient of the bioMérieux Sonnenwirth Award for Leadership in Clinical Microbiology. The award will be given during the 2013 General Meeting of the American Society for Microbiology (ASM) awards dinner in Denver on Sunday, May 19. Given in memory of Alexander Sonnenwirth, Ph.D., the award honors a top microbiologist for her or his innovation in clinical laboratory science, dedication to ASM and leadership in the microbiology field.

The award recognizes the advancement of clinical microbiology as a profession. It is sponsored since 1986, by bioMérieux the world leader in microbiology, and presented by ASM. As an active member of ASM for over thirty years and a leader in her field, Carey showcases the meaning of the award.

In 2004, Carey joined the Division of Healthcare Quality Promotion at CDC as Chief of the Clinical and Environmental Microbiology Branch, with responsibility for the reference laboratory overseeing identification and characterization of staphylococci and anaerobic bacteria, detection of antimicrobial resistance, and the investigation of healthcare associated infections. She also served as the Acting Director for the Division of Laboratory Systems, which provides technical and scientific oversight for the CLIA regulations that set the federal quality standards for the nation’s clinical laboratories.

She currently serves as Director of CDC’s Laboratory Quality Management Program with responsibilities for oversight of the quality management system for CDC Infectious Disease laboratories, for which she also serves as the Interim CLIA Director.

“It is a great honor for us to recognize Dr. Carey with this year’s bioMérieux Sonnenwirth Award for Leadership in Clinical Microbiology,” said Manuel O Méndez, Executive Vice President and General Manager, bioMérieux Americas. “We are very proud to give this award to an individual who shares our commitment to public health and improving patient outcomes and who has worked so tirelessly to improve the diagnosis of dangerous infections such as Shiga-toxin producing E. coli.”

She has been a member of the interdisciplinary workgroups that wrote CDC guidelines for diagnosis of Shiga-toxin producing E. coli and prevention of early-onset group B streptococcal infections. Currently she is serving as a member of the workgroup creating guidelines for Campylobacter Best Practices for Clinical and Public Health laboratories.

Carey graduated from William Smith College in Geneva, NY, with a Bachelor of Science, cum laude, in biology, received a Ph.D. in microbiology from Cornell University Graduate School of Medical Sciences, New York, NY, and completed a Post-doctoral Fellowship in Clinical and Public Health Microbiology at Temple University, Philadelphia, PA. She has been a diplomat of the American Board of Medical Microbiology in Public Health and Medical Microbiology since 1985.

To view Dr. Carey’s complete biosketch, please visit:

About the bioMérieux Sonnenwirth Award

The bioMérieux Sonnenwirth Award for Leadership in Clinical Microbiology will be presented during the 113th General Meeting of the ASM, May 18-21, 2013 in Denver, CO. ASM is the world’s oldest and largest life science organization and has more than 40,000 members worldwide. ASM’s mission is to advance the microbiological sciences and promote the use of scientific knowledge for improved health and economic and environmental well-being.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2012, revenues reached €1.57 billion with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN:FR0010096479).

Additional information can be found at


Media Relations

Allan Mohess
Tel: +1 919-479-3639

Baker & Yorke
Tim Baker
Tel: + 1 216-338-8086

Pioneering Diagnostics